Homocysteine levels and peripheral arterial occlusive disease: A prospective cohort study and review of the literature

Journal of Cardiovascular Surgery

Volumn 48, Issue 5, 2007, Pages 601-605

  Asfar, Sami ^a,b   Safar, H A ^a  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Atherosclerosis; Diabetes; Homocysteine; Peripheral vascular disease

Indexed keywords

HOMOCYSTEINE; LIPID;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HOSPITAL ADMISSION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KUWAIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; STROKE;

ADULT; AGED; ANKLE; ARTERIAL OCCLUSIVE DISEASES; BLOOD PRESSURE; BRACHIAL ARTERY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KUWAIT; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 36148974671     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Toohey JI.Possible involvement of sulfane sulfur in homocysteine-induced atherosclerosis. Med Hypotheses 2001;56:259-61.
2. McCully KS, Vascular pathology of homocystinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
3. Mudd SH, Levy HL, Skovby F. Disorder of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995.p.1279-327.
4. Wuillemin WA, Solenthaler M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis. Vasa 1999;28:151-5.
5. Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Lang T et al. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. J Lab Clin Med 1999;133: 575-82.
6. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA et al. Fasting and post-methionine homocysteine levels in NID-DM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125-32.
7. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996;57:S11-17.
8. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
9. Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am J Clin Nutr 2001;73:532-38.
10. 6 status on homocysteine metabolism. J Clin Invest 1996;98:177-84.
11. Aronow WS. Association between plasma homocysteine and vascular atherosclerotic disease in older persons. Prev Cardiol 2000;3:89-91.
12. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine level in plasma or serum: methods and clininal application. Clin Chem 1993;39:1764-79.
13. Scott CH, Sutton MS. Homocysteine: evidence for a causal relationship with cardiovascular disease. Cardiol Rev 1999;7:101-7.
14. Saw SM. Homocysteine and atherosclerotic disease: the epidemiologic evidence. Ann Acad Med Singapore 1999;28:565-8.
15. Taylor BV, Oudit GY, Evans M. Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature. Can Fam Physician 2000;46:2236-45.
16. Leowattana W, Mahanonda N, Bhuripunyo K, Pokum S. Association between serum homocysteine, vitamin B12, folate and Thai coronary artery disease patients. J Med Assoc Thai 2000;83:536-42.
17. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000;57:1422-7.
18. Pietrzik K, Bronstrup A. The role of homocysteine, folate and other B-vitamins in the development of atherosclerosis. Arch Latinoam Nutr 1997;47:9-12.
19. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
20. Fallest-Strobl PC, Koch DD, Stein JH, McBride PE. Homocysteine: a new risk factor for atherosclerosis. Am Fam Physician 1997;56:1607-12,1615-6.
21. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999;29:8-19.
22. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker; 1992.p.183-236.
23. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
24. Ubbink JB, Vermaak WJ, Delport R, van der Merwe A, Becker PJ, Potgieter H. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr 1995;62:802-8.
25. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
26. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
27. Starkebaum G, Harlan JM. Endothelial cell injury to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-6.
28. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial and areteriosclerosis in baboons. Circ Res 1983;53:731-9.
29. 6 on clinical outcome after percutaneous coronary intervention. JAMA 2002;288:973-9.
30. Ambrosi P, Rolland P, Garcon D. Homocysteine, a risk factor of atherosclerosis. Arch Mal Coeur Vaiss 1996;89:1667-71.
31. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
32. Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent GM et al. Higher plasma homocysteine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995;15:1314-20.
33. 12, folate, and risk of coronary artery disease in patients undergoing diagnostic coronary angiography. Amino Acids 2000;18:139-46.
34. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989-95.
35. 6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998;97:437-43.
36. Gibelin P, Candito M, Houenassi M, van Obberghen E, Morand P, Baudouy M. Blood levels of homocysteine in patients under 55 years of age with acute coronary insufficiency. Presse Med 1997;26:1425-8.
37. Reis RP, Azinheira J, Reis HP, Bordalo A, Santos L, Adao M et al. Homocysteinaemia after methionine overload as a coronary artery disease risk factor: importance of age and homocysteine levels. Coron Artery Dis 1995;6:851-6.
38. Kawashiri M, Kajinami K, Nohara A, Yagi K, Inazu A, Koizumi J et al. Plasma homocysteine level and development of coronary artery disease. Coron Artery Dis 1999;10:443-7.
39. Fernandez-Miranda C, Aranda JL, Gomez Gonzalez P, Diaz-Rubio P, Estenoz J, Gomez de la Camara A. Hyperhomocysteinemia is frequent in coronary disease patients. Study of 202 patients. Med Clin (Barc) 1999;113:407-10.
40. Yoo JH, Chung CS, Kang SS. Relation of plasma homocysteine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478-83.
41. Vila N, Deulofeu R, Chamorro A, Piera C. Plasma homocysteine levels in patients with ischemic cerebral infarction: Med Clin (Barc) 1998;110:605-8.
42. Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 1993;17: 687-9.
43. 6 plus folic acid therapy in young patients with arteriosderosis and hyperhomocysteinemia. J Vasc Surg 1994;20:933-40.
44. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997;11:217-23.
45. Nielsen NE, Brattstrom L, Hultberg B, Landgren F, Swahn E. Plasma total homocysteine levels in postmenopausal women with unstable coronary artery disease. Atherosclerosis 2000;151:423-31.
46. van den Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996;16:165-71.
47. Gerhard GT, Duell PB. Homocysteine and atherosclerosis. Curr Opin Lipidol 1999;10:417-28.
48. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-8.
49. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000;355:523-7.
50. Nedrebo BG, Ericsson UB, Nygard O, Refsum H, Ueland PM, Aakvaag A et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998;47:89-93.
51. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ et al. Association between plasma homocysteine concentrations and extra cranial carotid artery stenosis. N Engl J Med 1995;332:286-91.
52. Ballal RS, Jacobsen DW, Robinson K. Homocysteine: update on a new risk factor. Cleve Clin J Med 1997;64:543-9.
53. Marcucci R, Brunelli T, Giusti B, Fedi S, Pepe G, Poli D et al. The role of cysteine and homocysteine in venous and arterial thrombotic disease. Am J Clin Pathol 2001;116:56-60.
54. Stammler F, Diehm C, Hsu E, Stockinger K, Amendt K. The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically? Dtsch Med Wochenschr 1996;121:1417-23.
55. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
56. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM. Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis. Circulation 2001;104: 2442-6.
57. Jungers P, Joly D, Massy Z, Chauveau P, Nguyen AT, Aupetit J et al. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999;14:2903-6.
58. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999;34:669-77.
59. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-30.
60. Blom HJ, Boers GH, van den Elzen JP, van Roessel JJ, Trijbels JM, Tangerman A. Differences between pre-menopausal women and young men in the transamination pathway of methionine catabolism, and the protection against vascular disease. Eur J Clin Invest 1988;18:633-8.
61. Domagala TB, Libura M, Gozdecka H, Krzanowski M, Szczeklik A. Familial hyperhomocysteinemia with early development of atherosclerosis Pol Arch Med Wewn 1996;96:354-8.
62. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL Folic acidan innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215-221.
63. 6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
64. Malinow MR. Homocysteine, vitamins and genetic interactions in vascular disease. Can J Cardiol 1999;15:31B-34B.